LONG-TERM DEBT (Tables)

3 Months Ended

Oct. 28, 2023

The Company’s long-term debt consisted of the following:


(in millions)	Average Interest Rate at October 28, 2023	Fiscal Maturity Year	October 28, 2023		July 29, 2023
Term Loan Facility	8.68%	2026	$	670	$	670
ABL Credit Facility	6.78%	2027	1,152		812
Senior Notes	6.75%	2029	500		500
Other secured loans	4.43%	2025	5		9
Debt issuance costs, net			(20)		(22)
Original issue discount on debt			(6)		(6)
Long-term debt, including current portion			2,301		1,963
Less: current portion of long-term debt			(5)		(7)
Long-term debt			$	2,296	$	1,956

Schedule of Line of Credit Facilities

The assets included in the Condensed Consolidated Balance Sheets securing the outstanding obligations under the ABL Credit Facility on a first-priority basis were as follows:


(in millions)	October 28, 2023		July 29, 2023
Certain inventory assets included in Inventories, net	$	2,173	$	1,861
Certain receivables included in Accounts receivable, net	624		571
Pharmacy prescription files included in Intangible assets, net	9		11
Total	$	2,806	$	2,443

The Company’s unused credit under the ABL Credit Facility was as follows:


(in millions)	October 28, 2023
Total availability for ABL loans and letters of credit	$	2,550
ABL loans outstanding	(1,152)
Letters of credit outstanding	(150)
Unused credit	$	1,248

The applicable interest rates, unutilized commitment fees and letter of credit fees under the ABL Credit Facility are variable and are dependent upon the prior fiscal quarter’s daily Average Availability (as defined in the ABL Loan Agreement), and were as follows:


	Range of Facility Rates and Fees (per annum)	October 28, 2023
Borrowers’ applicable margin for base rate loans	0.00% - 0.25%	0.00	%
Borrowers’ applicable margin for SOFR and BA loans(1)	1.00% - 1.25%	1.00	%
Unutilized commitment fees	0.20%	0.20	%
Letter of credit fees	1.125% - 1.375%	1.125	%

(1) The U.S. Borrower utilizes SOFR-based loans and the Canadian Borrower utilizes bankers’ acceptance rate-based loans.